Filing summary
Company and period: The supplied filing is Caladrius Biosciences, Inc.’s Form 10-K for the fiscal year ended December 31, 2016, filed March 16, 2017. It is not a Lisata Therapeutics filing or a 2015 Q4 report.
Business context
Caladrius was developing early-stage cellular therapies, led by CLBS03, a Phase 2 autologous T-regulatory-cell candidate for adolescents with recent-onset type 1 diabetes. Its PCT subsidiary provided cell-therapy development and manufacturing services and generated more than 99% of reported revenue. After year-end, Caladrius agreed to sell its remaining 80.1% interest in PCT to Hitachi America; if completed, Caladrius would retain a substantially smaller cell-therapy development business.
Financial performance and liquidity
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Revenue | $35.3 million | $22.5 million |
| Gross profit / margin | $4.1 million / approximately 12% | $2.3 million / approximately 10% |
| Operating loss | $31.3 million | $113.8 million |
| Net loss | $33.3 million | $81.0 million |
| Net loss attributable to common stockholders | $32.7 million | $80.9 million |
| Cash used in operating activities | $23.7 million | $39.3 million |
Revenue increased 57%, principally from higher PCT clinical manufacturing and process-development activity. The smaller 2016 loss reflected lower operating expenses and the absence of 2015 impairment charges; 2015 included $62.3 million of goodwill and intangible-asset impairments, partly offset by other income and tax benefits. The filing reports no product-sale revenue.
At December 31, 2016, cash and cash equivalents were $14.7 million, working capital was approximately $5.1 million, and total stockholders’ equity was approximately $4.9 million. Long-term debt principal was approximately $5.7 million; notes payable were approximately $1.1 million. Cash declined from $20.3 million a year earlier. The auditor included a going-concern explanatory paragraph, citing recurring losses and substantial doubt about the Company’s ability to continue as a going concern.
Material changes, outlook, and risks
- Proposed PCT sale: The March 2017 agreement provides for $75 million in cash, subject to adjustments. It includes a $5 million initial payment, $5 million placed in escrow at closing, and a potential additional $5 million payment if PCT achieves $125 million of cumulative revenue (excluding clinical service reimbursables) during 2017–2018. Closing was expected in Q2 2017, subject to conditions including stockholder approval; completion was not assured. Sale proceeds were not reflected in the December 31, 2016 balance sheet.
- Conditional runway: Management expected sale proceeds to fund CLBS03 and other expenses for at least 12 months after issuance of the financial statements and to repay the Oxford Finance loan in 2017. Without the sale, additional financing was needed. The filing also notes that a private-placement investor had failed to fund $6 million and that receipt of those funds, plus a further $4 million commitment, was considered doubtful.
- Clinical and grant outlook: The CLBS03 Phase 2 trial had enrolled its first 19 patients and received a satisfactory safety review. An interim therapeutic-effect analysis was expected in late 2017 or early 2018. CIRM had awarded up to $12.2 million for the study, subject to milestones still under negotiation; $5.7 million was expected initially in April 2017.
- Pipeline changes: Caladrius discontinued development of CLBS10 after its ongoing Phase 2 trial and discontinued CLBS20 as a metastatic-melanoma monotherapy; it sought an out-licensing or combination-therapy partner for CLBS20. CLBS12 for critical limb ischemia in Japan remained dependent on a partner or other financing.
- Other transaction exposures: Failure to complete the PCT sale could trigger repayment of the initial payment and, in certain circumstances, a $5 million termination fee or an increase in Hitachi’s PCT ownership. The agreement also includes a five-year non-compete and non-solicitation period. Sale approval would accelerate outstanding unvested equity awards.
Most important facts for investors to verify
- Whether the PCT sale closed, the final cash proceeds after adjustments, debt repayment, transaction costs and escrow, and whether the contingent milestone is achievable.
- Actual cash runway and financing needs after the transaction, including the status of the disputed private-placement commitments and CIRM milestone funding.
- CLBS03 enrollment, interim efficacy results, safety findings, and the cost and funding plan for continued development.
- The post-sale company’s revenue base, operating costs, strategic plan, and ability to meet Nasdaq listing requirements.
- Potential indemnification, termination-fee, equity-acceleration, and other obligations associated with the PCT sale.